Oncology Archives - Page 17 of 22

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

Authors: D F McDermott, R Shah, K Gupte-Singh, J Sabater, L Luo, M Botteman, S Rao, M M Regan, M Atkins Published: Quality of life research, 2019 View publication Purpose To compare...

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Authors: A Shah, R Shah, N Kebede, A Mohamed, M Botteman, R Waldeck, A Hussain Published: Journal of Medical Economics, 2019 View publication Aims To describe the incidence and identify prognostic factors...

Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting

Authors: W Bouwmeester, A Briggs, B van Hout, R Hajek, S Gonzalez-McQuire, M Campioni, L DeCosta, L Brozova Published: Oncology and Therapy, 2019 View publication Introduction Risk stratification tools provide valuable information...

Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan

Authors: R Shah, M Botteman, R Waldeck Published: Future Oncology, 2019 View publication Aim We conducted this study to describe nonmetastatic castration-resistant prostate cancer (nmCRPC) patient characteristics and treatment patterns in the...

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

Authors: R Hájek, M Delforge, M S Raab, P Schoen, L DeCosta, I Spicka, J Radocha, L Pour, S Gonzalez-McQuire, W Bouwmeester Published: British Journal of Heamatology, 2019 View publication Abstract Multiple...

Treatment patterns and outcomes for patients with unresectable stage III and Metastatic Melanoma in the USA

Authors: A Tarhini, C Atzinger, K Gupte-Singh, C Johnson, C Macahilig, S Rao Published: Journal of Comparitive Effectiveness Research, 2019 View publication Aim To describe treatment patterns and outcomes of patients with...

A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of nivolumab versus everolimus in advanced renal cell carcinoma (aRCC)

Authors: R Shah, M Botteman, C T Solem, L Luo, J Doan, D Cella, R J Motzer Published: Clinical Genitourinary Cancer, 2019 View publication Background This analysis compared quality-adjusted time without symptoms...

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV): a trial-based analysis

Authors: M Botteman, K Nickel, S Corman, M Turini, G Binder Published: Supportive care in cancer: Official journal of the Multinational Association of Supportive Care in Cancer, 2019 View publication Purpose To...

Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting

Authors: S H Park, G Binder, S Corman, M Botteman Published: Journal of Medical Economics, 2019 View publication Background Chemotherapy-induced nausea and vomiting (CINV) are among the most common and debilitating side...

News